Cardiovascular events in chronic kidney disease (CKD)—an importance of vascular calcification and microcirculatory impairment by unknown
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In patients with chronic kidney disease (CKD), particularly in patients with hemodialysis, cardiovascular mortality rate
is extremely high. Polyvascular diseases develop at an early stage of CKD. Pathophysiology includes insulin
resistance and/or imbalance between nitric oxide (NO) and endothelin bioavailability as well as oxidative stress.
Overlooked pathophysiology may be hemorheological disarrangement because of hyperfibrinogenemia, and higher
rate of production for monocyte-platelet complexes in circulation, which plays an important role for atherosclerosis.
In terms of clinical findings, most of nephrologists have already known about the importance of coronary artery
disease, while few of nephrologists are aware of devastating influence of peripheral arterial disease (PAD) on
prognosis for the patients with CKD which is known to be one of the independent risk factors for PAD. The
understanding in pathophysiology of vascular calcification and strategic treatment is a critical issue to achieve
favorable outcome for the patients with CKD. In this regard, FGF-23 and associated factors together with Klotho
molecules play an important role.
In this article, we aim to review the cardiovascular disease for the patients with CKD with a particular emphasis on
the clinical aspects of polyvascular disease. Finally, we address to detect microcirculatory impairment and eradicate
vascular calcification as early as possible prior to renal replacement therapy. Apparently, FGF-23-Klotho gene axis as
well as vitamin D and phosphate control should be investigated vigorously.Background
It is well known that cardiovascular events (CVE)
increase as renal function declines [1]. Ohtake et al. have
reported that when renal replacement therapy (RRT) be-
gins, approximately 50 % of the patients with chronic
kidney disease (CKD) have significant coronary artery
stenosis regardless of the presence or absence of symp-
toms and/or signs. If the patients have diabetes, the
prevalence is reported to reach 89.9 % [2]. In this report,
all patients have no cardiac-related symptoms or signs
nor any treatment including percutaneous coronary
intervention (PCI), except hypertension. Although we
had reported that hypertension was an important risk
factor of lacunar infarction [3], we also revealed thatCorrespondence: shuzo@shonankamakura.or.jp
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symptoms [4]. These surprising results let us investigate
when and how cardiovascular complications develop
during a decrease in GFR. At the same time, it was re-
ported that CKD per se was an independent risk factor
for cardiovascular disorders (CVD) as an important
statement of AHA [5].
In this regard, the term, “polyvascular disease” has been
proposed [6, 7]. Polyvascular disease is defined as coexist-
ent symptomatic (clinically recognized) arterial disease in
two or three territories (coronary, cerebral, and/or periph-
eral) with each patient [6, 7]. Moreover, with regard to the
pathophysiology of atherosclerosis based on uremia, it has
been demonstrated that oxidative stress, thus leading to
endothelial dysfunction, plays an important role [8, 9]. We
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function [10]. Given that mineral and bone disorder plays
an important role in the patients with CKD, we need to
understand an impact of vascular calcifications on outcome
of CVD, because it makes an intervention difficult. In par-
ticular, the evidence that coronary calcification develops at
an early stage of CKD has been found with important find-
ings showing the roles of insulin resistance and asymmetric
dimethylarginine (ADMA) [11]. Moreover, because over-
looked findings are the issue concerning hemorheology [12],
we investigate a role of rheology [13, 14].
Of CVE, peripheral arterial disease (PAD), which
means in this context chronic atherosclerosis obliterans
(ASO) in the lower limbs, should be investigated more
sufficiently, given extremely poor prognosis after ampu-
tation in hemodialysis patients [15].
Insulin resistance and CKD
It has been shown that insulin resistance may contribute
to the pathogenesis of atherosclerotic cardiovascular dis-
ease [16]. It is widely known that hypertension and
hyperlipidemia play important roles in the progression
of renal disease [17] and that insulin resistance may be
involved in the pathogenesis of hypertension [18]. More-
over, nutritional, metabolic, and cardiovascular compli-
cations of renal disease may be consequences of
abnormal insulin action [19]. Therefore, long-standing
renal dysfunction may cause atherosclerosis prior to the
initiation of dialysis therapy. We have already reported
that both modalities of RRT, hemodialysis (HD), and
continuous ambulatory peritoneal dialysis (CAPD) im-
prove insulin resistance in patients with ESRD [20]. It
goes without saying that insulin resistance remains
among some patients after initiation of renal replace-
ment. It is reported that even in hemodialysis patients,
insulin resistance is an independent predictor of cardio-
vascular mortality in ESRD [21]. In CAPD patients, glu-
cose load during treatment affects insulin resistance,
which is associated with obesity [22].
All reports published recently show that insulin resist-
ance is present early in the course of renal disease [23–26].
However, a more precise method, hyperinsulinemic eugly-
cemic glucose clamp, to evaluate insulin sensitivity devel-
oped by DeFronzo et al. [27–29] has not been applied to
these studies. In addition, except classical risk factors such
as dyslipidemia or diabetes mellitus, affecting renal-related
factors associated with insulin resistance or apolipoprotrein
profiles have not yet been shown.
To address this issue in Japanese nondiabetic patients,
we carried out the hyperinsulinemic euglycemic glucose
clamp technique [30] to examine insulin sensitivity in
patients with different stages of renal function including
the stage just prior to the initiation of RRT and related
this with various affecting variables found in CKD. Inhealthy subjects, the glucose disposal rate (GDR) was
9.93 ± 1.33 mg/kg/min. In contrast, the GDR of patients
with CKD was 6.91 ± 2.46 mg/kg/min significantly lower
than that of healthy subjects (P < 0.01), which means di-
minished insulin sensitivity in patients with CKD. There
was a negative correlation between the GDR and serum
creatinine levels (r = 0.457, P < 0.05) (Fig. 1) and positive
correlations between the GDR and Ccr (r = 0.549, P <
0.01) or ApoA1/B (r = 0.396, P < 0.05). Of particular rele-
vance is the observed close correlation between the
GDR and HCO3 with extremely high predictive value for
the degree of acidosis (r = 0.611, P < 0.0005). Stepwise
multivariate regression analysis selected HCO3 (F value
13.28) and Apo A1/B (F 6.58) as independent contribut-
ing variables. The present study has many implications
for the management of renal patients before the initi-
ation of RRT because the discovered link between insu-
lin resistance and cardiovascular mortality in patients
with the metabolic syndrome. Every possible therapeutic
approach needs to be initiated very early to correct the
atherogenic metabolic profile. Particularly, the data sug-
gested that acidemia should be corrected as early as pos-
sible. Likewise, statin treatment may be used for the
correction of apolipoprotein profiles [31]. With regard
to the correction of acidemia, it has been reported that
the correction retards the progression of CKD [32]. It
became more evident that nontraditional risk factors
including insulin resistance, acidemia, and apolipopro-
tein would be involved in CVD found in CKD.
In addition to the factors described above, chronic
inflammation, oxidative stress, angiotensin II, and aldos-
terone also are known to be involved in insulin resist-
ance. With regard to mineral corticoid, it has been
reported that in a patient cohort with nondiabetic stage
2–5 CKD, estimated glomerular filtration rate (eGFR)
was negatively correlated and the plasma aldosterone
concentration was independently associated with the
homeostasis model assessment of insulin resistance. In
this report, spironolactone ameliorated insulin resistance
in these patients [33]. So far, there have been known
many factors that affect insulin resistance in CKD as
shown in Table 1.
Vascular calcification and insulin resistance in
CKD
Coronary artery calcification (CAC) is regarded as an
index of the severity of atherosclerotic vascular disease
and may predict future adverse cardiovascular events in
patients on dialysis [34–36]. In patients with CKD prior
to initiation of RRT, CAC is already present in the early
phase of CKD [37–39] and among diabetic nephropathy
[40]. Associated factors with CAC besides age, calcium,
phosphorus, iPTH, and inflammation have not been fully
elucidated. Arad et al. have reported that asymptomatic
Fig. 1 Insulin resistance develops at an early stage in CKD. The patients with at least serum creatinine more than 2 mg/dl clearly have insulin
resistance with hyperinsulinemic euglycemic glucose clamp method. GDR stands for glucose disposal rate, which is equivalent to glucose infusion rate
in order to set 100 mg/dl of serum glucose levels under insulin infusion
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ary calcification in general populations [41]. However, it
remains unknown whether insulin resistance is also cor-
related with CAC in CKD patients. Insulin resistance
leading to atherosclerosis may be explained by increased
plasma levels of ADMA, which is an endogenous nitric
oxide synthase inhibitor [42]. Concentrations of ADMA
are related to endothelial dysfunction [43, 44] because
increased ADMA may impair blood flow, accelerate
atherogenesis, and interfere with angiogenesis by inhibit-
ing the production of nitric oxide [45]. Of note, ADMA
concentrations are higher in dialysis patients withTable 1 Factors affecting insulin resistance
1. Anemia
2. PTH






9. Chronic inflammation (adipocytokine, adiponectin)
10. Aldosterone and angiotensin II
11. FGF-23
12. Gastrointestinal polypeptide (ghrelin)
13. Others (uremic toxin, p-cresyl sulfate)clinically manifest atherosclerosis than in those without
atherosclerotic disease [46], which suggests that accu-
mulation of ADMA might be an important cardiovascu-
lar risk factor in end-stage renal disease. Moreover, the
clinical importance of ADMA in coronary artery disease
is highlighted in a trial by Meinitzer et al. [47], in which
ADMA predicted cardiovascular events in 3200 patients.
In addition, ADMA predicts coronary events in middle-
aged Caucasian men [48].
With this background in mind, we aimed to study the
prevalence and associated factors of CAC in CKD pa-
tients prior to initiation of RRT [11]. Particularly, we
wanted to know whether insulin resistance and/or
plasma levels of ADMA would be correlated with CAC.
One hundred and eleven CKD patients (79 men, 32
women, GFR median 33.7 ml/min/1.73 m2), free of
cardiovascular disease, were consecutively recruited
along with 30 age-matched healthy subjects. Coronary
artery calcification scores (CACS) were measured by
multidetector-row CT (MDCT) according to Agatston
score, and insulin resistance was estimated by HOMA-
IR. In CKD patients, CACS was distributed widely from
0 to 2901(median 45), while in age-matched, healthy
control subjects (n = 30), CACS showed a range from 0
to 307 (median 2.8). GFR had a significant negative cor-
relation with CACS (r = 0.218, P < 0.05) (Fig. 2). Plasma
ADMA levels were negatively correlated with GFR (r =
−0.551, P < 0.001) and positively correlated with CACS
(r = 0.259, P < 0.05). When CACS was divided into quar-
tiles (<50, n = 56; 50~300, n = 24; 300~600, n = 14; >600,
GFR and Coronary artery calcification (CACS)  
ml/min/1.73m2
P<0.05 
Fig. 2 Coronary artery calcification assessed by Agatston calcium score (CACS) increases with a decline of GFR, when particularly in patients with
less than 45 ml/min/1.73 m2 of GFR, CACS is found to be abruptly increased
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cantly higher values of HOMA-IR, plasma ADMA
levels, and fibrinogen along with serum levels of phos-
phorus, compared with those in patients having CACS
below 50. Multivariate regression analysis determined
HOMA-IR (95 % CI 4.15–32.3, β value 0.257, P = 0.011)
as an independent contributing factor to CACS. We
demonstrated that CAC becomes more prevalent and
severe with a decline in GFR, and plasma ADMA
levels and insulin resistance, independent of factors
associated with CKD-MBD, are correlated with CAC
[11]. Despite the abovementioned findings, we should
also know the evidence that HOMA-IR was not pre-
dictive after adjustment for metabolic syndrome com-
ponents [49].
Hemorheological properties in CKD
Atherosclerosis is not a single disease entity, but a
process consisting of responses to numerous insults
to the endothelium, which plays an important role for
atherosclerosis. These cells function as a protective
biocompatible barrier between all tissues and the cir-
culating blood [50]. Therefore, endothelial cells are
likely to sense the changes in hemodynamic forces
and blood-borne signals. Injured endothelial cells are
predisposed to vasoconstriction, leukocytes adherence,
platelet activation, mitogenesis, and oxidation, all of
which lead to atherosclerosis. Particularly, evidence
suggests that leukocytes may play an active role in
the modulation of platelet function and vice versa
[50]. The formation of leukocyte aggregates (LA), par-
ticularly platelet-leukocyte aggregates, during HD mayplay an important pathophysiological role by facilitat-
ing platelet-endothelial interaction [51]. Indeed, in
myocardial infarction, and angina pectoris, it has been
reported that total binding of platelets to monocytes
increases, and there is an evidence showing that P-
selectin-independent molecular component plays an
important role [52].
We report [13, 14] that blood rheology could be
successfully evaluated using a micro-channel array
flow analyzer (MC-FAN) that makes it possible to
directly observe the flow of blood cell elements
through the micro-channel. Originally, in order to as-
sess hemorheological characteristics, MC-FAN was
developed to measure the transit time of 50 μl of
whole blood through micro-channels. During our
measurement of the transit time, we noticed many
aggregates of blood cell elements in micro-channels in
patients with HD. Using this method, we wanted to
show a significance of aggregates of blood cell ele-
ments found during blood flow through the micro-
channel array. This study sought to assess the rela-
tionship between leukocytes conjugated with platelets
(LA) and atherosclerosis in patients with HD. The
study included 118 patients on dialysis. As surrogate
markers of atherosclerosis, aortic stiffness measured
by brachial-ankle pulse wave velocity (baPWV) and
carotid intima-media thickness (IMT) were measured.
We measured a number of LA during 50-μl flow of whole
blood through micro-channels. In 12 age-matched healthy
individuals, a number of LA during 50-μl flow of whole
blood were 25.7 ± 5.4, whereas in dialysis patients, it was
significantly increased up to 48.2 ± 16.4 (P < 0.001). Flow
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monocyte-platelet complex. LA were positively associated
with plasma levels of fibrinogen (P < 0.01) or serum
hsCRP (P < 0.01). Moreover, LA had highly significant
associations with baPWV (P < 0.001) and IMT (P < 0.001).
As conclusions, we demonstrated hemorheologi-
cally that monocyte-platelet conjugates play an im-
portant role in aortic stiffness and IMT in CKD
patients.
Peripheral arterial disease in CKD—an importance
of an early detection of microcirculatory
impairment prior to dialysis
Peripheral arterial occlusive disease (PAD) influences the
mortality of patients on HD [53]. The early detection of
PAD is extremely important to improve the prognosis of
these patients. In this regard, various noninvasive
methods have been applied to the diagnosis of patients
with PAD [54–56]. The ankle-brachial blood pressure
index (ABI) is correlated well with the severity of PAD
symptoms and with the angiographic findings [56–59].
Therefore, the ABI is used as a standard tool for classify-
ing the severity of PAD or for assessment of the pres-
ence of critical limb ischemia [60, 61].
However, arterial rigidity associated with medial calci-
fication may interfere with the measurement of ABI.
Indeed, there are some cases in which it may be difficult
to detect isolated obstruction in one or even two of the
three branches of the popliteal artery between the knee
and ankle or obstruction in more distal vessels [56, 59].
These false-negative results occur in 17 to 24 % of
diabetic limbs and have also been reported in patients
undergoing HD or in other elderly patients [56, 62, 63].
Although usefulness of the toe-brachial pressure index
(TBI) or transcutaneous oxygen tension (tcPO2) has
been reported [64], Castronuovo et al. found that the
skin perfusion pressure (SPP) is an objective and nonin-
vasive method that can be used to diagnose critical limb
ischemia with an accuracy of approximately 80 % in
non-hemodialysis patients [65]. In the diabetic foot, SPP
is known to be correlated well with TBI [66]. Regarding
which of the noninvasive methods among ABI, TBI,
tcPO2, and SPP is superior to the others, we showed that
SPP is superior to others in terms of sensitivity and spe-
cificity [67]. The reason why ABI yields false-negative
results in HD patients may be greatly due to the fact that
the lesions in these patients often have arterial calcifica-
tion in addition to their location being in the more distal
parts of the lower limb arteries. We need to be aware
that microcirculatory impairment should be detected as
early as possible and take an action for the treatment of
vascular calcification.
In order to improve the outcome of PAD, it is ex-
tremely important to make intervention strategies forPAD [68]. Because the outcome for patients with foot
gangrene is poor, it is important to detect PAD as
early as possible prior to the initiation of dialysis.
Leskinen et al. [69] demonstrated that the patients
with CKD (mean creatinine levels 3.64 ± 1.53 mg/dl)
prior to the initiation of dialysis had PAD in 22 %
and medial arterial calcification in 23.7 %. It has been
also reported [70] that 32 % of patients had an ABI
< 0.9 in the patients with CKD 3~5 of K/DOQI
(mean eGFR 35 ± 12 ml/min/1.73 m2), and by the lo-
gistic regression analysis, independent indicators of
PAD risk were male sex, age, and lower Ccr. Twelve
percent of patients had an ABI ≥ 1.3, suggestive of
parietal arterial calcifications. In these patients, sys-
tolic blood pressure and pulse pressure were lower, i-
PTH levels were higher, and a larger proportion of
this group was treated with calcitriol (34 vs. 13 %)
compared to patients with a normal ABI. It is con-
cluded that a high prevalence of PAD, considered as
an ABI < 0.9, was demonstrated in nondialyzed pa-
tients with CKD. This was related with age, male sex,
and higher degree of renal insufficiency, while the
presence of ABI ≥ 1.3 was associated with a greater
degree of hyperparathyroidism. These data show the
need to carry out at least routine ABI determinations
including TBI in patients with CKD for early detec-
tion of peripheral arterial disease, and further SPP
would be more useful to detect microcirculatory
impairment. Regarding the treatment for the patients
with an ABI of 1.3 or higher, it is extremely an im-
portant issue in terms of a prevention of vascular cal-
cification. Thus, strict control of phosphorus as well
as avoiding drugs such as calcium-containing phos-
phate binders or warfarin which is known to decrease
matrix-gla protein working as a local inhibitor of
calcification [71].
CKD-MBD and vascular calcification—a role of
FGF-23 and phosphate control
It has been well known [72] that serum phosphate
levels are associated with mortality. Kestenbaum et al.
reported that after adjustment for confounding fac-
tors, serum phosphate levels >3.5 mg/dl were associ-
ated with a significantly increased risk for death.
Mortality risk increased linearly with each subsequent
0.5-mg/dl increase in serum phosphate levels. Elevated
serum phosphate levels were independently associated
with increased mortality risk among this population of
patients with CKD. There are several factors that
affect vascular calcification (Fig. 3). Pathogenesis of
vascular calcification is not merely the passive precipi-
tation of calcium and phosphate crystals but more
active process of trans-differentiation of vascular
smooth muscle cells into osteoblast-like cell. The
Fig. 3 Induction factors and inhibitors for vascular calcification are shown. Pathogenesis of vascular calcification is not merely the passive precipitation of
calcium and phosphate crystals but more active process of trans-differentiation of vascular smooth muscle cells into osteoblast-like cell
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inducers and inhibitors. Mitochondrial membrane
potential increases with increasing mitochondrial re-
active oxygen species, which activates the nuclear fac-
tor kB pathway followed by osteogenic genes and
mineralization. Of them, serum phosphate control and
discontinuation of drugs, which worsen vascular calci-
fication, can be achieved practically. Warfarin is
known to decrease active MGP (matrix-gla protein),
which is working as local inhibitor for calcification,
thus leading to calcification. The pathophysiology of
vascular calcification is beyond the scope of this re-
view. However, it is very important to understand the
rationale and approaches to phosphate and FGF-23
reduction in CKD [73]. Isakova et al. noted that obser-
vational studies report independent associations be-
tween elevated serum phosphate and fibroblast growth
factor 23 (FGF-23) levels and risks of ESRD, CVD, and
death. Phosphate excess induces arterial calcification,
and although elevated FGF-23 helps maintain serum
phosphate levels in the normal range in CKD, it may
contribute mechanistically to left ventricular hyper-
trophy (LVH). Consistent epidemiologic and experi-
mental findings suggest the need to test therapeutic
approaches that lower phosphate and FGF-23 in CKD.
Recently, Klotho gene was identified as a gene
mutated in a mouse strain that developed a prema-
ture aging syndrome. A defect in Klotho gene expres-
sion in mice results in shortened life span, muscleatrophy, vascular calcification, osteopenia, cognitive
impairment, all of which are found in CKD patients
[74]. Moreover, the fact that FGF23 requires Klotho
as a co-receptor explains why Klotho-deficient mice
develop phenotypes identical with those observed in
FGF23-deficient mice and why Klotho-deficient mice
had extremely high serum FGF23 levels. Taken to-
gether, we need to vigorously investigate FGF-23-
Klotho gene axis, in other words, kidney-bone axis as
well as vitamin D deficiency when we discuss about
cardiovascular complications. Indeed, it is reported
that lower 25-hydroxyvitamin D concentrations asso-
ciate with increased risk for incident CAC, and accel-
erated development of atherosclerosis may underlie,
in part, the increased cardiovascular risk associated
with vitamin D deficiency [75].
Apparently, we need to continue researching a role of
FGF-23 regarding cardiovascular events in progressive
stage in CKD prior to renal replacement therapy. Recently,
it has been reported that in the prospective observational
study of limited sample size, soluble Klotho was not sig-
nificantly related to cardiovascular outcomes. FGF-23 was
significantly associated with future decompensated heart
failure (CHF) but not incident atherosclerotic events [76].
An elevated level of fibroblast growth factor-23 (FGF-
23) is the earliest abnormality of mineral metabolism
in CKD. High FGF-23 levels promote left ventricular
hypertrophy but not coronary artery calcification.
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Fig. 4 Basic characteristics in pathophysiology of cardiovascular
disease in patients with CKD are shown. Cardiovascular
complications in CKD occur under the pathophysiology of
“vascular failure,” which means that intima and media both in
vessels are injured through nitric oxide and/or oxidative stress as
well as hypertension, dyslipidemia, and hyperuricemia
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Fig. 5 Increase pulse pressure due to vascular calcification plays an
important role of cardiac afterload and endothelial dysfunction,
which leads to vicious cycle for the progressive stage of vascular
injury leading to inflammation
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tients with CKD stages 2–4 [77].
Uric acid and cardiovascular events in CKD
Recent epidemiologic and experimental evidence sug-
gest that serum uric acid (UA) is an independent risk
factor for cardiovascular and renal diseases. The data
show an independent link between UA and endothe-
lial function, also in a statistical model that included
CRP [78].
UA may mediate aspects of the relationship be-
tween hypertension and kidney disease via renal vaso-
constriction and systemic hypertension. An elevated
serum UA level is an independent risk factor for inci-
dent kidney disease in the general population [79].
Recently, it has been reported that febuxostat slowed
the decline in eGFR in CKD stages 3 and 4 compared
to placebo [80]. Asymptomatic hyperuricemia could
be an important target to slow the progression of
CKD as well as a prevention of cardiovascular disor-
ders. Regarding uric acid levels and mortality, it is re-
ported that in multivariable models, a J- or U-shaped
relationship between serum uric acid level and total
or cause-specific cardiovascular mortality is observed.
There was not a linear increase in mortality from
almost all causes of death associated with the increase
in serum uric acid levels [81].
Conclusions
Although an important role of dyslipidemia and hyper-
tension was not described in this review, needless to say,
both has been long investigated regarding cardiovascular
complications in CKD.
Since Russell Ross reported the response-to-injury
hypothesis of atherosclerosis in 1976 followed by its up-
date in 1986, endothelial dysfunction with an important
role of monocytes-platelets has been investigated [82,
83]. Moreover, arterial intima and media calcification
both affect vascular calcification, which make the diag-
nosis and treatment extremely difficult. The media
calcification was described in 1903 Mönckeberk’s med-
iasclerosis after Professor Mönckeberg, pathologist, at
University Strasbourg [84]. Based upon these reasons,
cardiovascular events in CKD occur under the patho-
physiology of “vascular failure,” which mean that
intima and media both in vessels are injured (Fig. 4).
Increase pulse pressure due to vascular calcification
plays an important role of cardiac afterload and endo-
thelial dysfunction, which leads to vicious cycle for the
progressive stage of vascular injury leading to inflam-
mation (Fig. 5).
Microcirculatory impairment and vascular calcifica-
tion through endothelial dysfunction based on insulin
resistance should be detected as an early stage aspossible in CKD. Treatment strategies including phos-
phate, which indeed impairs endothelial function through
a reduction of nitric oxide production [85], and
correction of insulin resistance as well as traditional
treatment modalities are fundamental to improve
cardiovascular complications in CKD. Nephrologists
should be aware to treat the patients with CKD in
terms of polyvascular disease.
Apparently, FGF-23-Klotho gene axis as well as vita-
min D and phosphate control should be investigated
vigorously although precise roles of FGF-23 still remain
controversial [86].
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